Epirubicin in combination with the taxanes

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 12, 2001, Pages 41-50

  Trudeau, Maureen ^a   Pagani, Olivia ^a,b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CIPROFLOXACIN; CREMOPHOR; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; DOXORUBICINOL; DRUG METABOLITE; EPIRUBICIN; EPIRUBICINOL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PACLITAXEL; POLYSORBATE 80; TAXANE DERIVATIVE;

ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TISSUE LEVEL; DYSPNEA; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0034836344     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.26437     Document Type: Conference Paper

References (27)

1. Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper-type regimens
2. Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity
3. New cytotoxic drugs in the treatment of breast cancer
4. Anthracycline-induced cardiotoxicity
5. Anthracycline-induced cardiotoxicity and its relevance in cancer treatment
6. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
7. Combination doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
8. Sequence-dependent alteration of doxorubicin pharmacokinetics by pacitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
9. Human pharmacokinetic characterization and in vitro study of the interactions between doxorubicin and paclitaxel in patients with breast cancer
10. Compartive effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients
11. Paclitaxel induces significant changes in epidoxorubicin distribution in mice
12. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with Doxorubicin
13. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer
14. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: A preliminary report of safety
15. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer
16. A phase II trial of epirubicin plus pacliaxel in metastatic breast cancer
17. Escalating doses of docetaxel and epirubicin as first-line therapy for metastatic breast cancer. A phase I/II study of the National Cancer Institute of Canada Clinical Trials Group
18. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
19. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study
20. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexazoxane in patients with advanced breast cancer
21. European trials with dexazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity
22. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors
23. Phase II randomised trial of doxorubicin plus paclitaxel versus doxorubicin HCL liposome injection (Doxil) plus paclitaxel in metastatic breast cancer
24. Phase I trial of liposomal doxorubicin (Doxil) and docetaxel (Taxotere) in patients with advanced breast cancer
25. Docetaxel in combination with epirubicin as first-line chemotherapy of metastic breast cancer: Final results
26. First-line epirubicin and Taxotere in advanced breast cancer: A phase I study
27. Preoperative docetaxel/epirubicin in primary breast cancer